New capital will accelerate growth in Europe and expand the longevity company’s presence in APAC region.
Avea, a Switzerland-based longevity solutions company, has announced the successful completion of an extended seed funding round. The round, led by longevity company builder Maximon, their lead investor, has raised an additional $2.5 million, bringing Avea’s total seed funding to a healthy $5 million.
Longevity.Technology: This substantial injection of capital will further accelerate Avea’s growth trajectory in Europe, while also enabling the company to establish a robust presence in the APAC region. The extended funding round follows Avea’s recent launch of six products that have positioned the company in the longevity science market across Europe. Avea’s product line now includes NMN, collagen activator and antioxidants, as well as a DNA and epigenetics test.
“We are delighted to have secured this extended seed funding, which showcases the continued confidence and support from our lead investor, Maximon,” said Pascal Rode, COO and Co-founder at Avea. “This additional capital of $2.5 million brings our total seed funding to $5 million and positions Avea for even greater success as we expand our operations in Europe and want to establish a presence in the Asian market.”
Avea says the newly raised funds will be allocated towards various strategic initiatives, including expanding production capabilities, strengthening sales and marketing initiatives, reinforcing distribution networks across key European markets and conducting its first human studies. A significant portion of the investment will be dedicated to establish the company’s presence in Asia, capitalizing on the growing demand for longevity science products in this market.
Avea has set itself the goal of having an innovative,science-backed product portfolio; it reports that consumer demand has been high since its range of longevity solutions was introduced to the market. One popular item is Avea’s Collagen Activator, which was developed in partnership with scientists from the ETH (Eidgenössische Technische Hochschule) in Zurich, Switzerland. The Collagen Activator, which is currently pending patent approval is efficacious, demonstrating in research conducted at ETH that it was able to increase collagen synthesis significantly more than regular collagen intake in model organisms and mice.
“We are excited about the opportunities that lie ahead as we expand into the APAC market,” said Dr Tobias Reichmut, Founding Partner at Maximon. “With our well-established reputation in Europe and the outstanding results achieved with our products, including the highly acclaimed Collagen Activator, we are confident that Avea’s longevity science solutions will resonate with consumers in the APAC region, empowering them to lead healthier and more fulfilling lives.”
Marc P Bernegger, also Founding Partner at Maximon, told Longevity.Technology: “AVEA was the very first venture we founded with Maximon back in 2020. Since its launch in early 2021, the company is doing very well and serves a real need. By focusing on longevity supplements, AVEA is further expanding the market of longevity products for the broader masses. As a company builder and investor, we are planning to further support and boost AVEA‘s expansion in the coming months.”
Avea’s strategic partnership with Maximon, combined with the strong backing from its investors, looks to be a formula for success, positioning the company for continued success. The extended seed funding round represents a significant milestone for Avea and is a key step in its journey in the longevity science industry.
Main photo credit: Avea
Image shows (left to right): Pascal Rode (Chief Operating Officer), Teresa Budetta (Chief Marketing Officer) and Sophie Chabloz (Chief Product Officer)